Chimeric Therapeutics Limited · ASX:CHM

Chimeric Therapeutics — Investor Presentation (May 2025)

14 slides from Chimeric Therapeutics's investor presentation, May 22, 2025

  1. Slide 1: Chimeric Therapeutics: Pioneers in Cell Therapy

    For personal use only CHIMERIC CHI MERIC THE RAP EU TICS PIONEERS IN CELL THERAPY ASX: CHM C ONFID ENTIAL . NOT FOR DI STRI BUTI ON

  2. Slide 2: Disclaimer

    2 DISCLAIMER Certain statements contained in this presentation, including, without future events or developments except as required by law. For personal use only limitation, statements containing the words “believes,” “plans,” This presentation may not contain all the details and information “expect

  3. Slide 3: Investment Highlights and Corporate Profile

    INVESTMENT HIGHLIGHTS 4 4 Phase 1 clinical trials For personal use only CORPORATE PROFILE Multiple clinical updates Exchange ASX: CHM CHI MERIC THE RAP EU TICS Experienced leadership team Share Price $0.005 52 Week Range $0.004 - 0.047 the ONLY CDH17 CAR-T in clinical trials Market Cap Approx 10m Fi

  4. Slide 4: CHM: Broad Portfolio, Novel Cell Therapies in Clinical Trials

    4 CHM: BROAD PORTFOLIO 3 Novel cell therapies; 4 Clinical Trials For personal use only CHM CDH17 CHM CLTX CHM CORE-NK CAR-T CAR-T ‘OFF THE SHELF’ NK CHI MERIC THE RAP EU TICS PHASE 1B PHASE 1B TRIAL OPEN TRIAL OPEN PHASE 1/2 TRIAL OPEN PHASE 1B TRIAL OPEN 3 sites active 1 site active MD Anderson Cas

  5. Slide 5: CHM CDH17

    For personal use only CHI MERIC THE RAP EU TICS CHM CDH17 ASX: CHM C ONFID ENTIAL . NOT FOR DI STRI BUTI ON

  6. Slide 6: CHM CDH17 CAR-T Overview

    CHM CDH17 CAR-T OVERVIEW 6 The first CDH17 CAR-T cell therapy in clinical trials in the world For personal use only CHM CDH17 CAR-T targets an antigen on the surface/cell membrane of many cancer cells, called CDH17. Our CAR-T is unique, being the first CAR-T cell therapy under CHI MERIC THE RAP EU T

  7. Slide 7: CHM CDH17 CAR-T Phase 1/2 Rapidly Recruiting

    CHM CDH17 CAR-T PHASE 1/2 RAPIDLY RECRUITING 7 For personal use only Phase 1/2 open at 4 sites: UPENN, Sarah Cannon, Emory and UChicago PHASE 1/2 TRIAL OPEN RAPIDLY RECRUITING Cancer Targets: Gastric, Neuroendocrine Tumours and Colorectal CHI MERIC THE RAP EU TICS 15 patients to be recruited: 4 pati

  8. Slide 8: Clinical Preliminary Results

    CLINICAL PRELIMINARY RESULTS 8 CHM CDH17 DOSE LEVEL 1 For personal use only 50m Cells Tumour Type Status Patient 1 CRC Lost to follow up CHI MERIC THE RAP EU TICS Patient 2 NET Stable Disease until day 150 minor progression Patient 3 CRC Stable Disease day 90 Patient 4 CRC Progressive Disease CRC= C

  9. Slide 9: What's Next?

    WHAT’S NEXT? Safety clearance to Dose Level 2 For personal use only Patient 5,6,7 manufactured Commence dose level 2 – single dose of 150m cells CHI MERIC THE RAP EU TICS Monitor safety for 28days for patient 5 (FDA requirement) Patient 5 Patient 6 Patient 7 28 days 7 days EXAMPLE ONLY: Patient 5 Ju

  10. Slide 10: CHM CORE-NK

    For personal use only CHI MERIC THE RAP EU TICS CHM CORE-NK ASX: CHM C ONFID ENTIAL . NOT FOR DI STRI BUTI ON

  11. Slide 11: CHM CORE-NK Overview

    11 CHM CORE-NK OVERVIEW Phase 1b clinical trials being lead by partner institutions For personal use only CHM CORE-NK OFF THE SHELF: AKA ALLOGENEIC ‘OFF THE SHELF’ NK CHI MERIC THE RAP EU TICS NK cell expansion platform: Universal Donor Positive Phase 1A Clinical Trial in Colorectal Cancer (CRC) and

  12. Slide 12: AML Phase 1b Combination Clinical Trial Open

    AML PHASE 1B COMBINATION CLINICAL TRIAL OPEN CHM CORE-NK + AZA + VEN in front-line Acute Myeloid Leukaemia Clinical Trials.gov Identifier: NCT05834244 For personal use only CHI MERIC THE RAP EU TICS CORE NK CELLS FDA REGISTERED FDA REGISTERED CHEMOTHERAPY BLOOD CANCER DRUG Funded by our partners MD

  13. Slide 13: CHM CORE-NK Frontline Phase Study Results

    13 CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS Complete response in AML in two patient of first three dosed For personal use only 2 / 3 patients CORE-NK DIAGNOSIS: AML INFUSION CHI MERIC THE RAP EU TICS Not eligible for Chemo or Stem Patient Doses + SOC Cell Transplant COMPLETE RESPONSE i SAFETY: No

  14. Slide 14: Chimeric: Pioneers in Cell Therapy

    For personal use only CHIMERIC CHI MERIC THE RAP EU TICS PIONEERS IN CELL THERAPY investors@chimerictherapeutics.Com ASX: CHM C ONFID ENTIAL . NOT FOR DI STRI BUTI ON

Chimeric Therapeutics — Investor Presentation (May 2025) on 6ix